ArticleBMC ophthalmology2025
Evaluation of serum YKL-40 and Galectin-3 as predictive biomarkers for proliferative vitreoretinopathy in rhegmatogenous retinal detachment: a prospective comparative study.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- APRI and FIB-4 indices as systemic fibrosis markers in proliferative vitreoretinopathy.BMC ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the association between serum YKL-40 and Galectin-3 levels and the development of proliferative vitreoretinopathy (PVR) in patients with rhegmatogenous retinal detachment (RRD), and to evaluate their diagnostic and predictive value as potential biomarkers.
methodsEighty-eight subjects were divided into three groups: RRD with PVR (n = 32), RRD without PVR (n = 36), and healthy controls (n = 20). Serum YKL-40 and Galectin-3 concentrations were determined using ELISA. Clinical variables such as symptom duration and macular status were recorded. Group comparisons and regression analyses were used to assess associations with PVR development, and ROC analysis evaluated diagnostic performance.
resultsSerum YKL-40 and Galectin-3 levels were significantly higher in RRD patients than in controls (both p < 0.001). YKL-40 was markedly elevated in PVR (+) cases compared with PVR(–) and controls (p < 0.001 and p = 0.001), whereas Galectin-3 differed significantly only between PVR(+) and controls (p < 0.001). In multivariate logistic regression, higher YKL-40 (OR = 1.081, 95% CI 1.022–1.142, p = 0.006), Galectin-3 (OR = 1.029, 95% CI 1.004–1.054, p = 0.021), and delayed surgery (> 7 days) (p < 0.01) were independent predictors of PVR. ROC analysis between PVR (+) and PVR (–) groups demonstrated good diagnostic accuracy for YKL-40 (AUC = 0.739, p = 0.001; cut-off 26.9 ng/mL) and moderate accuracy for Galectin-3 (AUC = 0.643, p = 0.045; cut-off 99.7 pg/mL).
conclusionsElevated serum YKL-40 and Galectin-3 levels are associated with PVR development in RRD, reflecting underlying inflammatory and fibrotic activity. YKL-40 exhibited superior predictive performance, suggesting its potential as a systemic biomarker for identifying patients at risk of postoperative proliferation. Further studies incorporating intraocular biomarker profiling and targeted inhibition of these pathways may support novel adjunctive strategies to prevent PVR recurrence and improve surgical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.